{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-004616","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2024-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.066969+00:00","generated_at":"2026-06-06T23:17:45.478871+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA approves CRISPR's CASGEVY for transfusion-dependent beta thalassemia in patients 12+","bullets":["U.S. FDA approved CASGEVY (exagamglogene autotemcel) on Jan 16, 2024 for transfusion-dependent beta thalassemia in patients 12 years and older.","CASGEVY is a CRISPR/Cas9 gene-edited cell therapy developed by CRISPR Therapeutics.","The approval expands treatment options for patients with transfusion-dependent beta thalassemia."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-004616","json":"https://secwatch.observer/filing/0000950170-24-004616.json","markdown":"https://secwatch.observer/filing/0000950170-24-004616.md","text":"https://secwatch.observer/filing/0000950170-24-004616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024004616/0000950170-24-004616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024004616/crsp-20240116.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:17:45.478871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}